[Click eStock] "Curiox Biosystems, Growth Expected with New Product Launch"

Daishin Securities analyzed Curiox Biosystems on the 30th as a platform technology company leading the cell analysis automation market.

Songhyeop Han, a researcher at Daishin Securities, explained, "They will unveil new products at the CYTO and AAI conferences in May," adding, "They plan to launch them in the first half of this year." He further stated, "By releasing Pluto LT, which is 80% cheaper than the existing product (AUTO1000), they will capture the automation demand from small and medium-sized biotech companies."

He also emphasized, "The launch of Venus HT/Auto, capable of handling large-volume samples, will accelerate their entry into the diagnostics market," and noted, "18 out of the 20 global big pharma companies are clients." He analyzed, "Currently, the products are mainly used by R&D departments," and added, "We expect supply expansion to process development and overall production."

He explained, "Demand will increase for the development of gene-modified therapies such as CAR-T," and mentioned, "One of the major clients, Company G, has a potential demand for approximately 805 units."